Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Conditions
- B-Cell Prolymphocytic Leukemia
- Hypodiploidy
- Loss of Chromosome 17p
- Plasma Cell Leukemia
- Progression of Multiple Myeloma or Plasma Cell Leukemia
- Recurrent Adult Hodgkin Lymphoma
- Recurrent Adult Non-Hodgkin Lymphoma
- Recurrent Childhood Hodgkin Lymphoma
- Recurrent Childhood Non-Hodgkin Lymphoma
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Plasma Cell Myeloma
- Recurrent Small Lymphocytic Lymphoma
- Refractory Childhood Hodgkin Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Non-Hodgkin Lymphoma
- Refractory Plasma Cell Myeloma
- Refractory Small Lymphocytic Lymphoma
- t(14;16)
- t(4;14)
- T-Cell Prolymphocytic Leukemia
- Waldenstrom Macroglobulinemia
Interventions
- PROCEDURE: Allogeneic Bone Marrow Transplantation
- PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation
- PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation
- PROCEDURE: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation
- DRUG: Carmustine
- DRUG: Cyclophosphamide
- DRUG: Cytarabine
- DRUG: Etoposide
- DRUG: Fludarabine Phosphate
- OTHER: Laboratory Biomarker Analysis
- DRUG: Melphalan
- DRUG: Mycophenolate Mofetil
- PROCEDURE: Peripheral Blood Stem Cell Transplantation
- DRUG: Tacrolimus
- RADIATION: Total-Body Irradiation
Sponsor
Fred Hutchinson Cancer Center
Collaborators